Press release
Antisense Oligonucleotides Market Opportunity Analysis, 2026
Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen to treat cytomegalovirus retinitis, mipomersen to treat high cholesterol, etc.Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1879
Antisense Oligonucleotides Market Drivers:-
One of the major factors driving growth of the global antisense oligonucleotides market is increasing number of launches pertaining to novel Antisense Oligonucleotides products by key players in the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launched new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA is an alternative to existing siRNAs. LNA Antisense Oligonucleotide are designed using advanced bioinformatics algorithm, which is combined with LNA (locked nucleic acid).
Furthermore, mergers and acquisitions by key players, in order to enhance their product offerings is expected to be a major driver for global antisense oligonucleotides market growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life Sciences Ltd. to develop antisense oligonucleotides for central nervous system disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD), Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’s disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition will also help Takeda in gaining market share.
Robust pipeline is also another factor aiding in growth of the global market. For instance, in 2016 Ionis Pharmaceuticals completed phase 2 clinical trials of its ISIS CRP Rx. ISIS 329993 is an antisense oligonucleotide, which targets CRP (C reactive protein) in patients with paroxysmal atrial fibrillation. In 2015, Achieve Life Sciences completed Phase 2 clinical trials of its OGX 427. OGX 427 is used to treat castration resistant prostate cancer.
Antisense Oligonucleotides Market Regional Analysis:-
North America is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is owing to increasing approvals of new antisense oligonucleotide drugs in the region. For instance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinraza from Biogen Inc.—a multinational biotechnology company. Nusinersen is the first drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover, robust pipeline is expected to contribute significantly to North America antisense oligonucleotides market growth. For instance, in 2017, Bio Path Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001 (liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous leukemia.
Key players in Europe are focusing on strategic mergers and acquisitions in order to enhance their product offerings in antisense oligonucleotides. This is further expected to aid in growth of the Europe antisense oligonucleotides market size. For instance, in 2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceutical company—merged with Ionis Pharmaceuticals, a pharmaceutical company. Astra Zeneca Plc. has strategically merged with Ionis Pharmaceuticals to develop delivery methods for antisense oligonucleotides, which would help in targeting the desired tissue more effectively. The other objective of this merger was to develop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robust pipeline of key players is also expected to aid in growth of the market to a certain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceutical company completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT 3Rx is used in treatment of advanced cancers and lymphoma.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1879
Antisense Oligonucleotides Market Key Players:-
Key players in global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antisense Oligonucleotides Market Opportunity Analysis, 2026 here
News-ID: 1167031 • Views: …
More Releases from Coherent Market Insights

Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abb …
The Meal Replacement Market is estimated to be valued at USD 14.82 Bn in 2025 and is expected to reach USD 22.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.
The latest report from Coherent Market Insights examines the growth prospects of the Meal Replacement Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth…

Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion …
The deep cycle battery market is estimated to be valued at USD 2.77 billion in 2025 and is expected to reach USD 4.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
The latest report from Coherent Market Insights examines the growth prospects of the Deep Cycle Battery Market, Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business…

Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by …
The consumer electronics packaging market is estimated to be valued at USD 26.57 Bn in 2025 and is expected to reach USD 81.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2032.
The latest report from Coherent Market Insights examines the growth prospects of the Consumer Electronics Packaging Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,…

Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koni …
The global ceramic armor market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 4.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.
The latest report from Coherent Market Insights examines the growth prospects of the Ceramic Armor Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,…
More Releases for Antisense
Antisense Oligonucleotide Therapeutics Market
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease…
Antisense RNAi Therapeutics Market: Size, Share, and Trends Analysis
The antisense RNA interference (RNAi) therapeutics market represents a burgeoning sector within the pharmaceutical industry, offering innovative treatments for a wide range of diseases by modulating gene expression at the post-transcriptional level. Antisense RNAi therapeutics leverage the RNA interference mechanism to target specific messenger RNA (mRNA) molecules, thereby inhibiting the production of disease-associated proteins.
As of [current year], the market for antisense RNAi therapeutics is experiencing rapid growth, driven by advancements…
Antisense Oligonucleotide Therapeutics Market 2024-2031 | Exclusive Study Report
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease…
Current Trends: Antisense & RNAi Therapeutics Market in-depth Analysis
The global antisense & rnai therapeutics market is estimated to surpass $2,252.6 million by 2027, exhibiting a CAGR of 8.4% from 2020 to 2027.
The report offers a thorough analysis of global antisense & rnai therapeutics market with detailed study of various aspects of the market such as market dynamics, vital segments, major geographies, key players, and competitive landscape.
The report provides a clear picture of the current market situation and future…
Antisense Oligonucleotides Market Global Trends, Analysis and Forecast 2027
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning…
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Anal …
Summary
GlobalDatas "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, GlobalData provides an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights…